SubscribeThe Drug Information Association (DIA) today announced an alliance with The C-Path Institute, a non-profit organization whose purpose is to create programs in education and research to enable the safe acceleration of new medical product development.
Formed as a partnership between the FDA, The University of Arizona and SRI International, C-Path is a non-profit research and education corporation. Based in Tucson, Arizona, C-Path is the leading institution dedicated to the FDA’s Critical Path Initiative (CPI). The CPI developed as a result of the need to bring innovations into medical product design and development and accelerate the development of safe medical products.
“The CPI is a very hot topic in the industry right now,” said David Maola, executive director of DIA. “Our alliance with C-Path makes perfect sense: They are the authority on this topic and we are the industry’s premier organization for the exchange of information. It’s key for us (DIA) to develop relationships, such as this, that enhance our ability to address the latest and most important topics in the field.”
C-Path and DIA will work closely together to develop and provide programs and conferences to advance the CPI. The first conference under this new collaboration is titled Community Acquired Pneumonia: Critical Path Opportunities. The conference will be held on November 16 & 17, 2005 in Tucson, Arizona.
“We are pleased to combine forces with DIA, a highly respected, world wide leader for the exchange of information,” said Raymond Woosley, M.D., Ph.D., president and CEO of the C-Path Institute. “Like C-Path, DIA understands the need to provide a neutral forum for scientists from FDA, industry and academia to bring innovations into the process of medical product development. We believe this alliance will leverage our mutual strengths to serve the public health, the FDA and industry.”
About the Drug Information Association
The Drug Information Association serves over 25,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses and workshops, the DIA provides a neutral, global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, Pa., USA, the association is led by its volunteer-based Board of Directors and executive management team. For more information, please visit www.diahome.org or call +1 215 442 6100.